(via NewsDirect)
Leire highlighted the importance of this move as a strategic effort to stabilise and grow the company, especially noting the significance of attracting institutional investment. Historically, Genflow relied on grants and research funding, making this step a notable shift in its funding strategy.
Leire also mentioned the company's focus on longevity and healthspan, pointing out the increasing gap between lifespan and healthspan as a major healthcare and economic challenge. Genflow's approach to addressing age-related diseases has started to attract attention from the institutional market, recognizing the potential high upside in the longevity sector.
The funds raised are earmarked for continuing clinical trials in their three main programs: progeria, non-alcoholic steatohepatitis (NASH), and sarcopenia, aiming to reduce both financial and scientific risks by diversifying their portfolio.
Contact Details
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source